Publication:


abstract

The development of small molecule and antibody inhibitors targeting the interaction of receptor tyrosine kinases (RTKs), such as epidermal growth factor receptor (EGFR), is of high pharmacological and biological interest. Unfortunately, conventional biochemical techniques using cell or tissue lysates and co-immunoprecipitation experiments to investigate EGFR dimerization are not always conclusive. Here we describe a series of technical and biological validation experiments demonstrating the utility of a proximity ligation assay (PLA)-based methodology for in situ visualization and quantification of ligand-dependent EGFR receptor dimerization in intact cells. Using the PLA approach combined with a universally applicable epitope tagging strategy, we detected EGFR dimers in cells transiently co-expressing FLAG-tagged and MYC-tagged human EGFRs. Our data strongly suggest that PLA can be used to detect ligand-dependent EGFR dimerization and this signal is generated in a protein interaction-based manner, rather than solely due to proximity of target proteins. This application represents a generalized RTK expression strategy for protein-interaction analysis in a transient expression system where antibody epitopes are not known or not unique enough to discriminate between interaction partners. This assay also holds promise as a general RTK dimerization screening tool in tissue specimens to identify potential dimerization inhibitors with clinical relevance.

Related Articles
Cross-talk between the receptor tyrosine kinases Ron and epidermal growth factor receptor.
Exp Cell Res. 2003
Cross-talk between the receptor tyrosine kinases Ron and epidermal growth factor receptor.
Peace BE, Hill KJ, Degen SJ, Waltz SE. Exp Cell Res. 2003 Oct 1; 289(2):317-25.
Antibody-induced dimerization of HARPTPalpha-EGFR chimera suggests a ligand dependent mechanism of regulation for RPTPalpha.
FEBS Lett. 2000
Antibody-induced dimerization of HARPTPalpha-EGFR chimera suggests a ligand dependent mechanism of regulation for RPTPalpha.
Blanchetot C, den Hertog J. FEBS Lett. 2000 Nov 10; 484(3):235-40.
Immunodetection of the ligand-activated receptor for epidermal growth factor.
Growth Factors. 1991
Immunodetection of the ligand-activated receptor for epidermal growth factor.
Campos-González R, Glenney JR Jr. Growth Factors. 1991; 4(4):305-16.
Review Interactions between the epidermal growth factor receptor and type I protein kinase A: biological significance and therapeutic implications.
Clin Cancer Res. 1998
Review Interactions between the epidermal growth factor receptor and type I protein kinase A: biological significance and therapeutic implications.
Ciardiello F, Tortora G. Clin Cancer Res. 1998 Apr; 4(4):821-8.
Review Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Drugs Today (Barc). 2005
Review Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J, Burtness B. Drugs Today (Barc). 2005 Feb; 41(2):107-27.
Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action.
Breast Cancer Res. 2011
Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action.
DeFazio-Eli L, Strommen K, Dao-Pick T, Parry G, Goodman L, Winslow J. Breast Cancer Res. 2011 Apr 15; 13(2):R44. Epub 2011 Apr 15.
The IL-8-regulated chemokine receptor CXCR7 stimulates EGFR signaling to promote prostate cancer growth.
Cancer Res. 2011
The IL-8-regulated chemokine receptor CXCR7 stimulates EGFR signaling to promote prostate cancer growth.
Singh RK, Lokeshwar BL. Cancer Res. 2011 May 1; 71(9):3268-77. Epub 2011 Mar 11.
Time-resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using monoclonal antibodies.
J Biol Chem. 2011
Time-resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using monoclonal antibodies.
Gaborit N, Larbouret C, Vallaghe J, Peyrusson F, Bascoul-Mollevi C, Crapez E, Azria D, Chardès T, Poul MA, Mathis G, et al. J Biol Chem. 2011 Apr 1; 286(13):11337-45. Epub 2011 Jan 31.